


U.S. Serial No. 09/847,061  
 Attorney Docket No. P-092-US1  
 Customer No. 27038  
 Page 2

## II. Amendments to the Claims

Claims 1-6 (Cancelled).

7. (Currently Amended) The  $\Delta$  glycopeptide of claim 1 which is a compound of formula II:



(II)

wherein:

R<sup>3</sup> is -OH;

R<sup>5</sup> is hydrogen;

R<sup>19</sup> is hydrogen;

R<sup>20</sup> is  $R^a - Y - R^b - (Z)_x$ ,  $R^f - C(O)R^f$ , or  $C(O) - R^g - Y - R^b - (Z)_x$ ; and

U.S. Serial No. 09/847,061  
 Attorney Docket No. P-092-US1  
 Customer No. 27038  
 Page 3

$R^a$ , Y,  $R^b$ , Z, x,  $R^c$ ,  $R^d$ , and  $R^e$  have any of the values defined in claim 1;

$R^{20}$  is  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{Y}-\text{R}^b-(\text{Z})_x$  or  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{R}^{17}$ ;

$R^{17}$  is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic;

Y is selected from the group consisting of oxygen, sulfur,  $-\text{S}-\text{S}-$ ,  $-\text{NR}^c-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{SO}_2-$ ,  $-\text{NR}^c\text{C}(\text{O})-$ ,  $-\text{OSO}_2-$ ,  $-\text{OC}(\text{O})-$ ,  $-\text{NR}^c\text{SO}_2-$ ,  $-\text{C}(\text{O})\text{NR}^c-$ ,  $-\text{C}(\text{O})\text{O}-$ ,  $-\text{SO}_2\text{NR}^c-$ ,  $-\text{SO}_2\text{O}-$ ,  $-\text{P}(\text{O})(\text{OR}^e)\text{O}-$ ,  $-\text{P}(\text{O})(\text{OR}^e)\text{NR}^c-$ ,  $-\text{OP}(\text{O})(\text{OR}^e)\text{O}-$ ,  $-\text{OP}(\text{O})(\text{OR}^e)\text{NR}^c-$ ,  $-\text{OC}(\text{O})\text{O}-$ ,  $-\text{NR}^c\text{C}(\text{O})\text{O}-$ ,  $-\text{NR}^c\text{C}(\text{O})\text{NR}^c-$ ,  $-\text{OC}(\text{O})\text{NR}^c-$ ,  $-\text{C}(=\text{O})-$  and  $-\text{NR}^c\text{SO}_2\text{NR}^c-$ ;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

$R^b$  is selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided  $R^b$  is not a covalent bond when Z is hydrogen;

each  $R^c$  is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and  $-\text{C}(\text{O})\text{R}^d$ ;

each  $R^d$  is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; and

x is 1 or 2;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.

Claims 8-12 (Canceled).

U.S. Serial No. 09/847,061  
Attorney Docket No. P-092-US1  
Customer No. 27038  
Page 4

13. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of ~~claim 1~~ Claim 7.

14. (Currently Amended) The pharmaceutical composition of claim 13, which wherein the composition further comprises a cyclodextrin.

Claim 15 (Canceled).

16. (Original) A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide of claim 7.

17. (Original) A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of claim 13.

18. (New) The glycopeptide of Claim 7, wherein  $R^{20}$  is  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{R}^{17}$  and  $\text{R}^{17}$  is alkyl.

19. (New) The glycopeptide of Claim 7, wherein  $R^{20}$  is  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{R}^{17}$  and  $\text{R}^{17}$  is aryl.

20. (New) The glycopeptide of Claim 7, wherein  $R^{20}$  is  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{Y}-\text{R}^b-(\text{Z})_x$  and  $\text{Y}$  is  $-\text{NH}-$ .

21. (New) The glycopeptide of Claim 7, wherein  $R^{20}$  is  $-\text{CH}_2-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{CH}_2-\text{Y}-\text{R}^b-(\text{Z})_x$  and  $\text{Y}$  is oxygen.


U.S. Serial No. 09/847,061  
 Attorney Docket No. P-092-US1  
 Customer No. 27038  
 Page 5

22. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is -CH<sub>2</sub>-CH(OH)CH(OH)CH<sub>2</sub>-Y-R<sup>b</sup>-(Z)<sub>x</sub> and Y is sulfur.


23. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is -CH<sub>2</sub>-CH(OH)CH(OH)CH<sub>2</sub>-Y-R<sup>b</sup>-(Z)<sub>x</sub> and R<sup>b</sup> is alkylene.

24. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is -CH<sub>2</sub> CH(OH)CH(OH)CH<sub>2</sub>-Y-R<sup>b</sup>-(Z)<sub>x</sub> and Z is hydrogen.


25. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is a group of the formula:



26. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is a group of the formula:



27. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is a group of the formula:



U.S. Serial No. 09/847,061  
Attorney Docket No. P-092-US1  
Customer No. 27038  
Page 6

28. (New) The glycopeptide of Claim 7, wherein R<sup>20</sup> is a group of the formula:

